Clinical Trial: Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity)

U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07757568) titled 'Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity)' on Sept. 12, 2025.

Brief Summary: The investigators propose a multi-center pilot study, which aims to evaluate safety and efficacy of fumarates as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.

Study Start Date: March 07, 2023

Study Type: OBSERVATIONAL

Condition: Multiple Sclerosis (MS) Relapsing Remitting

Intervention: DRUG: Vumerity

Titration starting with 231 mg twice a day, orally, for 7 days (per United States Product information). Then cont...